Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Support

This activity is supported by educational grants from AstraZeneca; Athenex Oncology; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc; Genomic Health, Inc; Gilead Sciences; Hologic, Inc; KCI USA, Inc; Lilly; Novartis Pharmaceuticals Corporation; Puma Biotechnology, Inc; and Seagen.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

38th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™

Release Date: May 25, 2021
Expiration Date: May 25, 2022

Activity Overview

Breast cancer represents a complicated family of diseases for which detection, diagnosis, and multimodal management strategies are continually evolving. With each lesson learned about the biology of these diseases, and with each improvement to the standards of care, new questions, challenges, and controversies arise. Therefore, practice-focused education that enables you to integrate the highest-quality methodologies into your clinic is essential.

This Clinical Case Vignette Series™ program provides an in-depth review of some of the key highlights from the 38th Annual Miami Breast Cancer Conference® held in March 2021. This unique and engaging multimedia activity consists of expert interviews on challenging clinical cases and other topics important to the practicing community clinician. These experts explore different clinical vignettes and provide evidence-based strategies, as well as discussion of current clinical data that are changing outcomes for patients with breast cancer. The program is designed for those who did not view the live webcast and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca; Athenex Oncology; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc; Genomic Health, Inc; Gilead Sciences; Hologic, Inc; KCI USA, Inc; Lilly; Novartis Pharmaceuticals Corporation; Puma Biotechnology, Inc; and Seagen.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is intended for medical, surgical, and radiation oncologists; pathologists; and nurses/nurse practitioners interested in the treatment of patients with breast cancer. Fellows, physician assistants, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Integrate validated biomarkers, multigene assays, and tumor subtype information, as appropriate, to inform clinical decision-making and personalize therapy for patients with breast cancer
  • Utilize multidisciplinary treatment planning to incorporate evidence-based surgical, radiation, and systemic therapeutic approaches when appropriate to ensure optimal outcomes for patients with non-metastatic breast cancer
  • Incorporate high-level evidence from clinical trials of systemic therapies, along with expert guidance, into treatment planning to provide individualized care and optimized outcomes for patients with breast cancer
  • Describe ongoing clinical trials evaluating investigational agents and strategies that may offer additional treatment options for patients with breast cancer
  • Coordinate a multidisciplinary team-based approach to prevent, mitigate, and manage treatment-related adverse events for patients undergoing treatment for breast cancer to reduce the risk of harm while maintaining efficacy

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Adam M. Brufsky, MD, PhD
Adam M. Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Division of Hematology/Oncology
Co-Director, Comprehensive Breast Cancer Center
University of Pittsburgh Medical Center – Hillman Cancer Center
University of Pittsburgh Medical Center – Magee-Womens Hospital
University of Pittsburgh
Pittsburgh, PA

Disclosures: Consultant: Agendia, Bioarray, Biotheranostics, Celgene, Eisai, Eli Lilly and Company, Genomic Health, NanoString Technologies, Novartis Pharmaceuticals, Pfizer, Roche.

Sara A. Hurvitz, MD
Sara A. Hurvitz, MD
Professor of Medicine
Director, Breast Cancer Clinical Research Program
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Santa Monica, CA

Disclosures: Grant/Research Support: Contracted research Ambrx, Amgen, Arvinas Biotech, Bayer, Daiichi Sankyo, Dignitana, Eli Lilly and Company, Genentech, GlaxoSmithKline, Immunomedics, MacroGenics, Novartis Pharmaceuticals, OBI Pharma, Pfizer, Pieris, Puma Biotechnology, Radius Health, Roche, Sanofi, Seattle Genetics; Shareholder: NKMAX; Other: Travel – Lilly.

Hope S. Rugo, MD, FASCO
Hope S. Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosures: Grant/Research Support: Daiichi Sankyo, Eisai, Eli Lilly and Company, Genentech, Immunomedics, MacroGenics, Merck & Co, Novartis Pharmaceuticals, OBI Pharma, Odonate Therapeutics, Pfizer, Seattle Genetics, Sermonix Pharmaceuticals; Consultant: Samsung (Limited Consulting); Other: Travel: AstraZeneca, Daiichi Sankyo, MacroGenics, Merck & Co, Mylan Pharmaceuticals, Novartis Pharmaceuticals and Pfizer. Honoraria: Puma Biotechnology and Mylan Pharmaceuticals.

Debu Tripathy, MD
Debu Tripathy, MD
Professor and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: Novartis Pharmaceuticals, Polyphor; Consultant: AstraZeneca, GlaxoSmithKline, Genomic Health, Novartis Pharmaceuticals, Pfizer, OncoPep.

Pat W. Whitworth, MD
Pat W. Whitworth, MD
Director
Nashville Breast Center
Nashville, TN

Disclosures: Grant/Research Support: Targeted Medical Education, LLC; Consultant: Agendia, Bard, Exact Sciences, Myriad Pharmaceuticals, Prelude Therapeutics, Puma Biotechnology; Shareholder: Advantage Consulting and Education, Advantage Clinical Research, Nashville Breast Center, Targeted Medical Education.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
2627282930
Filter By